On September 13, local time, GlaxoSmithKline issued a statement saying that the drug Jideytro achieved a clinically significant 94% objective remission rate in ROS1-positive non-small cell lung cancer patients who were not treated with tyrosine kinase inhibitors in the registered phase I/II Arros-1 trial.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.